← Eichor
Condition: Recurrent Meningioma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Recurrent Meningioma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Apatinib in the Treatment of Recurrent Atypical/malignant Meningioma in Adults
NA · 1 location(s) · Beijing Sanbo Brain Hospital · NCT04501705RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma
Phase 1/Phase 2 · 1 location(s) · Joshua Palmer · NCT07150806Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
Phase 2 · 1 location(s) · Mayo Clinic · NCT04082520Adjuvant Hypofractionated Stereotactic Radiosurgery for Intermediate-risk Meningioma
NA · 1 location(s) · University of California, San Francisco · NCT06557512NEO100 and High-Grade Meningioma
Phase 2 · 5 location(s) · Neonc Technologies, Inc. · NCT05023018Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3
Phase 2 · 8 location(s) · Northwestern University · NCT02847559Regorafenib for Recurrent Meningioma (MIRAGE Trial)
Phase 2 · 17 location(s) · Istituto Oncologico Veneto IRCCS · NCT06275919Search for Circulating Tumour Cells in the Blood and/or Cerebrospinal Fluid in Patients With Recurrent Aggressive Mening
NA · 1 location(s) · University Hospital, Montpellier · NCT07398170Treatment of Recurrent or Progressive Meningiomas With the Radiolabelled Somatostatin Antagonist 177Lu-satoreotide
Phase 1/Phase 2 · 1 location(s) · University Hospital, Basel, Switzerland · NCT04997317Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treat
Phase 1/Phase 2 · 1 location(s) · Fundación de investigación HM · NCT06607692Cabozantinib for Patients With Recurrent or Progressive Meningioma
Phase 2 · 3 location(s) · Baptist Health South Florida · NCT05425004Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Phase 1 · 1 location(s) · Jazz Pharmaceuticals · NCT04541082A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
Phase 2 · 12 location(s) · Exelixis · NCT07428616Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
Phase N/A · 54 location(s) · GT Medical Technologies, Inc. · NCT04427384Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
Phase 1/Phase 2 · 4 location(s) · Nationwide Children's Hospital · NCT05278208Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Phase 2 · 780 location(s) · Alliance for Clinical Trials in Oncology · NCT02523014177Lu-DOTATATE for Recurrent Meningioma
Phase 2 · 19 location(s) · European Organisation for Research and Treatment of Cancer - · NCT06326190
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.